Retatrutide Phase 3 TRIUMPH-1 and TRIUMPH-4 results and Taltz-Zepbound Phase 3b TOGETHER-PsA data announced
Positive clinical evidence may expand the addressable market and strengthen the future product pipeline.
The findings are positive pipeline evidence, especially for potential expansion of retatrutide into knee osteoarthritis and integrated immunometabolic treatment. However, the release is a summary rather than a complete clinical report; retatrutide remains investigational. No score change is justified yet.